Illumina shines in Q1; Cook launches GI bleeding device;

@FierceMedDev: Thermo soars after Life Tech deal and dials up its expectations. Story | Follow @FierceMedDev

@VarunSaxena2: Federal court postpones Edwards' block of Medtronic's CoreValve. More | Follow @VarunSaxena2

@EmilyWFierce: Cleveland startup won JDRF support for its rapid-acting insulin analog for Type 1 diabetes. News | Follow @EmilyWFierce

@MichaelGFierce: X-ray-activated nanoparticles release #cancer-killing light deeper into tissue. More from FierceDrugDelivery | Follow @MichaelGFierce

> Illumina's ($ILMN) revenue jumped 27% to $421 million in the first quarter, and net income came in at $60 million, beating a $23 million loss from the same period last year. Results

> Cook Medical has launched its Instinct Endoscopic Hemoclip around the globe, marketing a device designed to stop bleeding in the gastrointestinal tract. News

> Siemens ($SI) won FDA clearance for Somatom Force, a computed tomography imaging device. Release

Biotech News

@FierceBiotech: Shooting for IPO glory, Alder cites trial success with migraine drug. More | Follow @FierceBiotech

@JohnCFierce: Amgen beats a path to the FDA, looking for an early approval of leukemia drug. Story | Follow @JohnCFierce

@DamianFierce: BMY pal Alder hit the mark in a migraine trial, good news on the eve of its IPO. News | Follow @DamianFierce

@EmilyMFierce: TB drug could be basis for class of broad-spectrum treatments. More from VaccinesNewsDaily | Follow @EmilyMFierce

> Kala reels in $22.5M to get its next-gen eye drops into PhIII. News

> Spectrum touts PhII cancer data, plans NDA. Item

> Allergan fashions a poison pill as raiders at Valeant promise to gut R&D. Story

Pharma News

@FiercePharma: Google exec figures pharma could go viral on YouTube--if it tried. More from FiercePharmaMarketing. | Follow @FiercePharma

@TracyStaton: $16B deal for GlaxoSmithKline oncology meds turns Novartis into cancer heavyweight. Story | Follow @TracyStaton

@EricPFierce: Gilead turns in eye-popping results because of huge sales of Sovaldi, $2.3B in Q1 sales for the hep C drug. News | Follow @EricPFierce

@CarlyHFierce: Big Pharma sees danger, not safety, in U.S. FDA's new social media guidance. Article | Follow @CarlyHFierce

> Payer revolt notwithstanding, Gilead's Sovaldi earns crown as fastest drug launch ever. News

> Amgen's $4.5B in Q1 sales lags estimates, thanks to slow-selling Enbrel. More

> Biogen sales leap 50% on blockbuster-level Tecfidera sales. Story

> NICE rejects Roche's hot new breast cancer drug Kadclya, then invites negotiations. Article

Drug Delivery News

> Hydrocarbon double-stapling of peptides a new trick in fight against viruses. Report

> Mylan launches first generic transdermal contraceptive patch. News

> X-ray-activated nanoparticles release cancer-killing light deeper into tissue. Article

> Stanford team finds that nanotubes catch a ride with immune cells to reach tumors. More

> DNA nanocages that act like viruses bypass the immune system to deliver drugs. Story

> ProNAi, with delivery tech licensed from Marina, snags $59.5M for cancer trials. Item

Diagnostics News

> MDxHealth broadens reach of prostate cancer Dx with new U.S. PPO deal. News

> Investors initially respond well to Abbott's diagnostics gains. More

> Cepheid's 2014 Q1 produced Dx sales hikes but also more losses. Report

> UW-Madison team concocts asthma blood Dx that could work before symptoms appear. Story

> KineMed, with IPO in sight, joins global diabetes biomarker research project. Article

Pharma Marketing News

> Google exec figures pharma could go viral on YouTube--if it tried. News

> Big Pharma sees danger, not safety, in FDA's new social media guidance. Story

> It's official: Gilead's Sovaldi zooms past previous records with fastest-ever drug launch. Article

> Allergan sales force key to Valeant chief's plans for post-merger growth. Report

> Doc offices that nix free samples cut way back on branded scripts: JAMA study. More

> Lilly nabs FDA approval for its blockbuster cancer hopeful ramucirumab. Item

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.